← Browse by Condition
Medical Condition
intrahepatic cholangiocarcinoma
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for intrahepatic cholangiocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — intrahepatic cholangiocarcinoma Clinical Trials
How many clinical trials are currently recruiting for intrahepatic cholangiocarcinoma?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for intrahepatic cholangiocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for intrahepatic cholangiocarcinoma?
intrahepatic cholangiocarcinoma research spans Phase 1 (1 trial), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a intrahepatic cholangiocarcinoma clinical trial?
Eligibility criteria for intrahepatic cholangiocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 3
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT04556214
Recruiting
Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial)
Enrollment
15 pts
Location
Norway
Sponsor
Oslo University Hospital
NCT06505486
Recruiting
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Enrollment
21 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
NCT07223307 Phase 2
Recruiting
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Enrollment
62 pts
Location
United States
Sponsor
Stanford University
NCT07169734 Phase 1, Phase 2
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Enrollment
180 pts
Location
United States, Franc...
Sponsor
Alentis Therapeutics AG
NCT06296563 Phase 2
Recruiting
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
Enrollment
20 pts
Location
China
Sponsor
Lei ZHAO
NCT06098547
Recruiting
LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)
Enrollment
10 pts
Location
Italy
Sponsor
Azienda Sanitaria Ospedaliera
NCT06643208
Recruiting
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Enrollment
37 pts
Location
China
Sponsor
Fujian Provincial Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology